KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group

Background In the Children’s Oncology Group ANBL1221 phase 2 trial for patients with first relapse/first declaration of refractory high-risk neuroblastoma, irinotecan and temozolomide (I/T) combined with either temsirolimus (TEMS) or immunotherapy (the anti-GD2 antibody dinutuximab (DIN) and granulo...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Rajen Mody, KyungMann Kim, Paul M Sondel, Amy K Erbe, Julie Park, Sabah Servaes, Jen Birstler, Wendy B London, Jung-Tung Hung, Alice L Yu, John M Maris, Mitch B Diccianni, Arlene Naranjo, Fan F Zhang, Arika S Feils, Barry L Shulkin, Varsha Mathew, Marguerite T Parisi, Shahab Asgharzadeh, Rochelle Bagatell
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMJ Publishing Group 2023-02-01
Schriftenreihe:	Journal for ImmunoTherapy of Cancer
Online-Zugang:	https://jitc.bmj.com/content/11/2/e006530.full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!